ABENHA MEDICAL JOURNAL emj
Print ISSN 1110-208X
Online ISSN 2357-0016

Review article

CRISPR-Based Gene Editing in Human Medicine: Clinical Potentials and Ethical Dilemmas

Saghya Infant Shofia, Sundaram V, Sowndharya Balamurugan B, Mathan Muthu C M, Saravanan A, Jenila Rani D

Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, 602105, India

Correspondence to: Sundaram V, Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, 602105, India

Email:

hodbiotech.sse@saveetha.com

Received: 3 July 2025

Accepted: 3 August 2025

Abstract:

CRISPR-mediated gene editing has already revolutionized human medicine with its unprecedented precision and efficiency in editing genetic mutations. Technologically, it is CRISPR-Cas9-based and can introduce precise genome modifications, and has therapeutic potential for monogenic diseases, cancers and infectious diseases. On the clinical front, such results have indicated that certain early-phase trials for β-thalassemia and sickle cell disease using CRISPR-Cas9 have achieved up to 90% decrease in the dependency on transfusions and more than 85% increase in haemoglobin levels, which are tangible results. In the oncologic setting, CRISPR-modified T cells have been employed in immunotherapy trials and have demonstrated enhanced tumour killing of some hematopoietic malignancies. In addition, infusion of SG cells has allowed editing of hematopoietic stem cells outside the human body, in a controlled and relatively safe setting, a condition absolute for clinical translation. Yet, the technology has significant ethical issues, particularly germline editing, long-term off-target effects, and accessibility. A case in point involves the CRISPR-edited embryos scandal in China, which revealed the absence of a worldwide agreement on regulation as well as the dangers of premature clinical application. Similarly, the cost of CRISPR-based therapies ($1 million plus per patient) serves to widen that divide, especially in LIMCs. As clinical uses extend, there is an urgent need to develop strong ethical frameworks and ways to monitor long-term safety, and to ensure that the technologies are equitably accessible, to incorporate CRISPR into health systems responsibly.

Keywords: Health equity, Genetic disorders, β-thalassemia, Sickle cell disease, Immunotherapy

Introduction

With the revolutionary gene-editing technique known as CRISPR—clustered regularly interspaced short palindromic repeats—molecular biology and genetics have changed dramatically. This strong instrument lets researchers specifically alter DNA in many species, including people, animals, and plants. A guide RNA (gRNA) aiming at a particular DNA sequence and a CRISPR-associated (Cas) endonuclease, usually Cas9, cutting the designated DNA comprise CRISPR technology (1). Creating and synthesising the guide RNA, forming the Cas9-gRNA complex, target recognition, DNA cleavage, and DNA repair via non-homologous end joining (NHEJ) or homology-directed repair (HDR) define the CRISPR system's mechanism. Over earlier gene-editing approaches, CRISPR provides advantages of precision, efficiency, flexibility, and affordability. Its widespread acceptance has spurred a variety of uses in fundamental research, agriculture, medicine, biotechnology, and environmental preservation (2). Still, ethical concerns and legislative obstacles including off-target effects, germline editing, ecological effect, equitable access, and establishing suitable regulatory systems persist. Researchers are improving the specificity, efficiency, and distribution methods of CRISPR technology as it advances; with fresh variants like base editing and prime editing enlarging its capabilities. Ongoing research and development in CRISPR technology promise to revolutionize genetics, medicine, and biotechnology, therefore altering disease treatment, crop yields, and world problems (3).

Over several decades, CRISPR's evolution from a bacterial defence mechanism to a revolutionary gene-editing device covers many years. Japanese scientists found strange repetitive DNA sequences in E. coli in 1987, which they later dubbed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). Researchers first noticed in 2005 CRISPR's participation in bacterial adaptive immunity, noting it as part of bacteria's immune system against viral infections and proposing a memory-based defence mechanism. When scientists proved CRISPR-Cas9 to be a programmable gene-editing technology, paving the path for accurate gene editing in several species (4), the year 2012 marked a turning point. CRISPR was used successfully in eukaryotic cells in 2013 to modify genes in mouse and human cells, therefore opening doors for possible medical uses and genetic research. Year 2015 saw the first CRISPER-edited human embryos for research purposes, which raised ethical issues and started worldwide debates about gene editing limitations. The contentious birth of the first CRISPR-edited human babies was announced in 2018, provoking broad criticism and calls for more rigorous laws. Further emphasizing the relevance of CRISPR technology was the awarding of the Nobel Prize in Chemistry to Emmanuelle Charpentier and Jennifer Doudna in 2020 for their ground-breaking work in developing CRISPR-Cas9 as a gene-editing tool (5). Other milestones include the first CRISPR clinical tests for cancer immunotherapy in 2016, the correction of a disease-causing mutation in human embryos in 2017, the beginning of US

CRISPR gene therapy clinical trials in 2019, and the FDA authorization of the first CRISPR-based diagnostic test for SARS-CoV-2 in 2021. Ongoing research focuses on perfecting CRISPR methods, exploring applications in agriculture and environmental conservation, creating therapies for genetic diseases, and addressing ethical and regulatory issues. These accomplishments emphasize CRISPR's quick evolution and its ability to revolutionize genetic research and therapy while also raising important ethical and societal concerns (6). CRISPR development spans from basic discoveries in bacteria to therapeutic applications in humans as shown in fig 1.



Fig1: Chronological Milestones in the Discovery and Development of CRISPR Technology

MECHANISM OF CRISPR-CAS SYSTEMS

Crispr-Cas9 and Its Variants

Developed from bacteria's adaptive immune systems, CRISPR-Cas9 is a groundbreaking gene-editing technology. Two main parts comprise this system: the Cas9 endonuclease and a guide RNA (gRNA). Guiding the Cas9 enzyme to the target site, the gRNA is meant to match a particular DNA sequence. Once Cas9 gets at the target, it induces a double-strand break in the DNA (7). Through two routes—non-homologous end joining (NHEJ) and homology-directed repair (HDR)—the cellular repair systems address the break. NHEJ is an error-prone repair process that often results in small insertions or deletions at the break site, thereby interfering with gene function. More exact than other repair methods, HDR uses a template DNA sequence to repair the break, therefore enabling the insertion of particular genetic alterations. These repair mechanisms let scientists manipulate genes by either interfering with their activity or adding chosen alterations (8). Because of the CRISPR-Cas9 system's adaptability, many Cas9 versions have

been created to solve particular constraints or extend the tool's possibilities. These varieties include SpCas9-HF1 (High-Fidelity Cas9), which shows mutations that diminish non-specific DNA interactions thereby significantly lowering off-target effects without sacrificing on-target efficacy; eSpCas9 (Enhanced Specificity Cas9) exhibits decreased off-target effects by means of alterations that weaken non-specific DNA contacts; xCas9, an evolved Cas9 variant with greater PAM recognition, enabling targeting of formerly inaccessible genomic sites; Cas9 nickase, a changed Cas9 that produces single-strand nicks instead of double-strand cuts, thereby improving specificity when utilized in pairs; and dCas9 (Dead Cas9), a catalytically inactive type of Cas9 that can bind to DNA without cleavage, useful for gene regulation applications such as activating or repressing gene expression when conjugated with appropriate effector domains (9,10).

With more exact control over gene editing, these Cas9 mutations have considerably increased the CRISPR toolset and opened the possible uses of CRISPR technology for scientists. Some other applications and developments include base editing—which employs dCas9 fused with deaminase enzymes to do exact single-nucleotide changes without producing double-strand breaks—and prime editing, a more flexible method capable of carrying out all kinds of gene edits without depending on double-strand breaks or donor DNA templates. Utilizing dCas9 combined with epigenetic modifiers, epigenome editing changes DNA methylation or histone modifications to alter gene expression (11). dCas9 joined with repressor or activator domains enables CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to modulate gene expression without modifying the DNA sequence. With multiplexed editing, several gRNAs enable simultaneous targeting of several genes, hence facilitating more complicated genetic changes. Developing distribution techniques for CRISPR components in vivo gene editing allows for gene editing in living species, with possible therapeutic uses (12).

CRISPR libraries are used in genome-wide screening to execute high-throughput functional genomics experiments, hence identifying gene functions and possible drug targets. These developments have propelled CRISPR technology beyond basic gene editing and made it possible to apply it in many fields including medicine, agriculture, and biotech. Ongoing research improves the specificity, efficiency, and adaptability of CRISPR tools, thereby increasing their potential influence on scientific inquiry and therapeutic applications (13).

Off-Target Effects and Specificity Control

Still a major obstacle in CRISPR-Cas9 gene editing, off-target effects could cause unforeseen genetic changes. Researchers have created and improved several approaches to increase specificity and reduce off-target occurrences in answer to this issue. These techniques include prime editing, base editors, regulated Cas9 expression, Cas9 protein engineering, and optimized gRNA design. Design of optimized gRNAs involves using sophisticated computer algorithms to anticipate possible off-target sites, integrating machine learning techniques to enhance prediction accuracy, designing

gRNAs with little homology to off-target areas, and accounting for chromatin accessibility and epigenetic elements in gRNA choice (14,15). Engineered Cas9 proteins emphasize the development of high-fidelity Cas9 variants via rational design and directed evolution, the introduction of mutations improving target discrimination, the production of Cas9 orthologs from several bacterial species with naturally higher specificity, and the engineering of Cas9 variants with decreased non-specific DNA binding. Controlled Cas9 expression tactics include implementing inducible expression systems to regulate Cas9 levels temporally, using tissue-specific promoters for targeted Cas9 expression, employing self-limiting Cas9 systems that reduce expression after initial editing, and optimizing Cas9 dosage and exposure time to minimize off-target effects (16).

Base editors have been developed for accurate single-nucleotide changes; efforts to construct base editors with constricted editing windows to enhance specificity, create dual-function base editors for concurrent C-to-T and A-to-G conversions, and optimize base editor architectures to reduce RNA off-target effects have been made (3). CRISPR-Cas9 gene editing relies on two important methods for off-target detection: GUIDE-seq and DISCOVER-seq. Implementing GUIDE-seq enables objective, genome-wide off-target detection; DISCOVER-seq facilitates in vivo off-target analysis. To improve these techniques, machine learning algorithms can be included for precise off-target site prediction and modified sequencing techniques can be created for greater sensitivity. Another crucial component of CRISPR technology is Cas9 ribonucleoprotein (RNP) delivery (17). While designing cell type-specific delivery systems helps targeted editing, optimizing RNP composition will improve cellular uptake and stability. Novel nanoparticle-based delivery systems can be investigated for improved performance, and combining RNP delivery with other approaches might further minimize off-target effects.

Promising avenues for investigation are alternative CRISPR nucleases like Cas12a (Cpf1) and other Cas variations with naturally higher specificity (18). Engineered versions of these alternative nucleases can be made for improved performance; RNA-targeting CRISPR systems like Cas13's potential can be investigated for particular applications. Using Cas9 nickase pairs, the paired nickase strategy creates targeted double-strand breaks with diminished off-target effects. Optimizing the design of paired gRNAs can improve efficiency and specificity; designing computer programs can help select best nickase target sites (19). Finally, ensuring the safety and effectiveness of CRISPR-based therapies depends on off-target effect prediction and verification. Utilizing several computational prediction tools allows for full off-target analysis; establishing standardized protocols for experimental off-target validation guarantees consistency. Implementing high-throughput sequencing methods allows genome-wide off-target detection; guidelines for evaluating the biological significance of detected off-target events help in determining the overall impact of CRISPR-mediated gene editing (20). Table 1 explains the CRISPR based interventions in human diseases.

Table 1: Therapeutic Frontiers: CRISPR-Based Interventions in Human Diseases (21-32)

Application Area	Disease/Condition	CRISPR Target	Therapeutic Strategy	Clinical Stage	Remarks	Reference
Genetic Disorders	Sickle Cell Disease	HBB gene	Gene correction in hematopoietic cells	Phase I/II trials	First-in-human CRISPR therapy (e.g., exa-cel)	21
Genetic Disorders	Duchenne Muscular Dystrophy (DMD)	DMD gene	Exon skipping or gene repair	Preclinical	Focus on restoring dystrophin production	22
Eye Diseases	Leber Congenital Amaurosis (LCA10)	CEP290 mutation	In vivo gene editing	Phase I/II	Uses direct injection into the eye	23
Cancer Immunotherapy	Various cancers (e.g., leukaemia)	PD-1, TCR genes	Engineering T cells	Clinical trials	CRISPR-edited CAR-T and TCR-T cells	24
Infectious Diseases	HIV	CCR5 gene	Knockout of CCR5 receptor	Preclinical	Prevents HIV entry into T cells	25
Infectious Diseases	HPV-induced cervical cancer	E6/E7 oncogenes	Disruption of viral oncogenes	Preclinical	Targeting HPV DNA in cancerous cells	26
Neurological Disorders	Huntington's Disease	HTT gene	Gene silencing	Preclinical	Focused on lowering mutant protein	27
Neurological Disorders	Amyotrophic Lateral Sclerosis (ALS)	C9orf72 mutation	Repeat excision	Preclinical	For familial ALS with gene expansion	28
Metabolic Disorders	Familial Hypercholesterolemia	PCSK9 gene	Gene disruption	Preclinical	Targets liver for cholesterol regulation	29
Blood Disorders	Beta Thalassemia	HBB or BCL11A gene	Reactivation of fetal haemoglobin	Phase I/II trials	Uses ex vivo editing of stem cells	30
Liver Diseases	Hereditary Tyrosinemia Type I	FAH gene	Gene correction	Preclinical	Demonstrated in animal models	31
Dermatological Disorders	Epidermolysis Bullosa	COL7A1 gene	Ex vivo correction in skin cells	Preclinical	Aim to restore skin integrity	32

CLINICAL APPLICATIONS OF CRISPR IN HUMAN MEDICINE

Monogenic Disorders: β-Thalassemia and Sickle Cell Disease

Particularly in β-thalassemia and sickle cell disease, CRISAR-Cas9 technology has shown great promise in treating monogenic diseases. Mutations in the β-globin gene cause these hereditary blood diseases, which lead to aberrant haemoglobin synthesis and a range of clinical symptoms (33). Two primary approaches based on CRISPR target treatment for β-thalassemia: correcting the mutated β-globin gene to restore normal haemoglobin production and reactivating fetal haemoglobin (HbF) synthesis to make up for deficient adult haemoglobin. Promising results have been seen in clinical trials, with successful gene editing in hematopoietic stem cells (HSCs) accomplished. Patients treated with changed HSCs have displayed higher levels of healthy haemoglobin, lowered transfusion requirements and enhancing quality of life for some individuals (34).

The ex vivo modifying procedure involves harvesting HSCs from the patient, modifying the cells employing CRISPR-Cas9 technology, and retransplanting the edited cells back into the patient. Challenges include maximizing editing effectiveness and guaranteeing long-term safety. CRISPR techniques target the BCL11A gene, which inhibits fetal haemoglobin production, in sickle cell disease treatment. Early clinical trials have shown good outcomes; some patients have shown improvements in symptoms including fewer pain crises, some have attained transfusion dependence, and lower frequency and severity of vaso-occlusive events (35,36). Common targets for CRISPR editing in treatment of sickle cell disease is the BCL11A gene, which suppresses fetal haemoglobin synthesis. Constant study seeks to increase the specificity and efficiency of gene editing methods. Among the challenges and future directions are developing more effective in vivo gene editing delivery methods, correcting possible off-target effects and unintended genetic changes, increasing accessibility and lowering the price of gene treatment, and investigating combined treatments combining CRISPR with other therapeutic techniques. Guaranteeing the long-term safety and effectiveness of CRISPR-based therapies is one of them (37).

Oncology: Gene-Edited T Cell Therapies

Especially in the creation of gene-edited T cell treatments, CRISPR technology has transformed cancer immunotherapy and greatly improved the effectiveness and adaptability of several immunological techniques. CRISPR is utilized in CAR-T cell therapy to remove inhibitory genes such PD-1 and CTLA-4, which usually function as "brakes" on the immune system, therefore making T cells more aggressive in attacking cancer cells. Furthermore, permitting the insertion of genes enhancing T cell lifetime and cytotoxic potential, it facilitates a more sustained and strong anti-tumour reaction (38). By deleting genes causing graft-versus-host disease, CRISPR also allows the production of "off-the-shelf" CAR-T cells from donor T cells, therefore increasing treatment affordability and availability. CRISPR enables accurate

changes in TCR-T cell therapy to boost the binding strength of T cell receptors to cancer-specific antigens, to introduce engineered TCR genes more efficiently targeting particular tumours, and to eliminate indigenous TCR genes so minimizing the risk of TCR mispairing and maybe autoimmune reactions (39).

Overcoming checkpoint inhibitor resistance calls on many different techniques using CRISPR technology. PD-L1 knockout in cancer cells lowers their vulnerability to immune attack by eradicating their expression. By altering genes implicated in antigen processing and presentation, antigen presentation alteration improves T cell tumour cell recognition. Epigenetic regulator targeting changes variables affecting checkpoint inhibitor resistance. Combination therapies include designing CAR-T cells with integrated checkpoint inhibition and altering T cells to express both CARs and engineered TCRs for wider targeting ability (40,41).

Modifying T cells for hypoxia resistance, metabolic enhancement, and immunosuppressive molecule degradation helps to address tumour microenvironment problems. Safety and side effect reduction strategies include incorporating suicide genes, changing CAR activation thresholds, and producing inducible CAR systems. Manufacturing and scalability improvements center on optimizing gene editing techniques, creating universal donor T cells, and investigating fresh CRISPR delivery techniques. Together, these developments help to produce more efficient, safer, and more generally applicable cancer immunotherapies, therefore transforming cancer therapy strategies (42,43).

Infectious Diseases and Antiviral Applications

CRISPR technology provides creative ways to fight contagious illnesses and create antiviral therapies. CRISPR-based techniques in HIV treatment seek to alter the CCR5 gene in T cells, which codes for a co-receptor used by HIV to enter cells. Disrupting this receptor will hopefully produce HIV-resistant T cells that might provide long-term immunity against infection. Targeting and excising integrated HIV proviral DNA from infected cells, CRISPER systems are also being developed to overcome a significant barrier in HIV cure research (44). CRISPR is under investigation in conjunction with other gene therapy techniques, such as CAR-T cell therapy, to boost the immunological response against HIV-infected cells. For hepatitis B, CRISPR systems are being designed to precisely target and cleave hepatitis B virus (HBV) DNA, maybe curing chronic HBV infection.

CRISPR-based strategies aim to eliminate the persistent form of HBV DNA in infected hepatocytes, therefore achieving a complete cure (45). Researchers are developing liver-targeted delivery systems for CRISPR components to improve efficacy and reduce off-target effects in HBV treatment. In antiviral applications, CRISPR-Cas systems can be engineered to recognize and cut specific viral DNA or RNA sequences in infected cells, hence limiting viral replication and spread. CRISPR-based approaches may offer protection against a broad spectrum of viral pathogens by targeting conserved regions throughout several viral families. CRISPR technology is also being explored for creating genetically modified cells or

organisms resistant to viral infections, thereby helping to prevent disease outbreaks (46).

Emerging infectious diseases are a great worldwide health issue, but CRISPR technology provides hopeful cures. Quick and sensitive detection of newly emerging pathogens is made possible by CRISPR-based diagnostic tools like SHERLOCK and DETECTR, therefore enabling quick reactions. CRISPR technology speeds the process in vaccine development by enabling rapid alteration of viral genomes to produce attenuated strains (6). Moreover, CRISPR technologies offers a flexible basis for creating therapies against emerging infectious diseases by quickly adapted to target newly discovered viral infections. These uses show how adaptable and promising CRISPR technology is in the fight against several infectious illnesses. With efforts concentrated on improving delivery techniques, increasing specificity, and reducing off-target effects to guarantee safety and efficacy in clinical contexts, ongoing research and clinical trials keep broadening the therapeutic possibilities of CRISPR-based treatments in human medicine (47,48). CRISPR-Cas9 enables targeted gene editing through guide RNA-directed DNA cleavage, followed by cellular repair mechanisms like non-homologous end joining (NHEJ) or homology-directed repair (HDR) as shown in fig 2.



Fig 2: Mechanism of CRISPR-Cas9 Mediated Genome Editing: Gene Deletion and Insertion Pathways

THERAPEUTIC OUTCOMES AND QUANTITATIVE DATA FROM CLINICAL TRIALS

Safety and Efficacy Metrics

Assessing the therapeutic effects of novel therapies or interventions depends on quantitative evidence provided by safety and efficacy measures, which are essential parts in assessing the success of clinical trials. Regulatory agencies like the FDA rely on these measures to assess the risk-benefit profile of fresh medications prior to approval.

Safety measures cover adverse event rates, gauging the frequency and seriousness of unintended medical events during the study; serious adverse event rates, including life-threatening events, hospitalizations, or events causing major disability; treatment discontinuation rates owing to side effects, reflecting the tolerability of the therapy; changes in vital signs or laboratory measures include blood pressure, heart rate, liver function tests, or other relevant biomarkers; long-term safety data gathered over extended follow-up periods to assess deferred or cumulative effects; and drug interactions, assessing possible interactions with other drugs or substances (49,50).

Primary endpoint achievement rates make up the major outcome measures specified in the study protocol; secondary endpoint achievement rates offer more outcome measures that support the primary endpoint; time to response or remission measures the period needed for the treatment to exhibit a detectable effect; duration of response or remission assesses the period the treatment effect lasts; quality of life assessments includes patient-reported outcomes evaluating general well-being and function; biomarker changes reflect alterations in particular biological markers linked to the disease or therapy; dose-response relationship evaluates efficacy at various doses of treatment; and subgroup analysis examines treatment effects in certain patient groups (51,52).

Evaluating the safety and efficacy of novel therapies in clinical trials depends critically on statistical analyses and regulatory issues. Statistical analysis spans several methodologies, including per-protocol analysis, which concentrates on patients who finished the study as planned, and intent-to-treat analysis, which includes all randomized participants regardless of adherence or withdrawal. While multivariate analysis considers many variables that may affect results (53), survival analysis is used for time-to-event data such as progression-free survival or overall survival.

Post-marketing surveillance guarantees ongoing safety and efficacy monitoring following approval, while actual-world evidence provides data gathered outside of regulated clinical trial environments to aid in regulatory decisions. These more extensive measures and analyses offer a more complete framework for assessing novel therapies, therefore guaranteeing a complete evaluation before regulatory approval and use in clinical practice (54,55).

Case Studies and Success Rates

Individual patient experiences are closely studied in case studies, therefore providing insightful observations on the practical application of therapies. Often stressing a few essential features are these studies. First, they check patient demographics and medical history, which comprise age, gender, ethnicity, comorbidities, pre-existing conditions, family history of relevant diseases, and lifestyle elements including diet, exercise, and smoking status. Secondly, they describe therapy methods and dosages, including particular drugs or treatments employed, dosing and frequency of administration, length of treatment, combination treatments if appropriate, and any changes made to usual protocols (56).

Thirdly, case studies examine the reaction to treatment over time—initial response, rate of improvement, biomarker changes or imaging findings, symptom reduction or clearance, quality of life evaluations, and adherence and compliance. Fourthly, they discuss the management of side effects, comprising kinds and degree of negative occurrences, actions taken to lessen those effects, effects on therapy continuance or dose modifications, and long-run repercussions. Finally, case studies investigate long-term results including recurrence rates, functional status and quality of life, influence on general health and well-being, follow-up care and monitoring, as well as disease progression or remission condition (57).

Usually reported employing a few main measures are success rates gotten from case reports and clinical trials. Useful for gauging general treatment efficacy, the Overall Response Rate (ORR) is the percentage of patients reaching a predetermined degree of response, including partial as well as total responses. The Complete Response Rate (CR) indicates the proportion of patients exhibiting full disease remission, usually linked with superior long-term results and perhaps further categorized (e. g., pathological CR, molecular CR) (58), usually defined as a specified percentage reduction in tumour size or disease burden.

The Partial Response Rate (PR) reflects the proportion of patients exhibiting considerable improvement but not total resolution, therefore helping to evaluate advantages in non-curative environments. Progress-Free Survival (PFS) reflects the median period from beginning of treatment to disease progression or death, therefore showing the duration of therapeutic benefit and often utilized as a major endpoint in clinical trials.

Regarded as the gold standard endpoint in oncology trials, overall survival (OS) represents the median time from treatment commencement to death from any cause, thereby assessing advantages in non-curative environments (59,60).

These rates let one compare several treatment choices by being shown usually as percentages or median time ranges. To find patient groups that might profit most from a certain treatment, researchers may also do subgroup analyses. Through the combination of quantitative data from large-scale clinical studies and thorough case studies, healthcare professionals can make informed decisions about treatment choices, set realistic expectations about possible outcomes for patients, customize treatment plans to fit specific patient

needs, advance ongoing research and treatment development, and improve patient education and shared decision-making. Stratification by age groups, gender, or ethnic group; evaluation based on particular genetic markers or biomarkers; assessment of efficacy in patients with different disease stages or previous treatments; and comparison of outcomes in patients with various comorbidities are among these studies (61,62). This all-encompassing approach allows healthcare professionals to evaluate individual patient success probabilities, balance possible benefits against risks and side effects, investigate alternative therapies or combination treatments, explore predicted response rates and timelines, describe possible side effects and management strategies, tackle long-term prognosis and quality of life concerns, change dosage or schedule according to patient characteristics, implement preventive measures for expected side effects, include supportive care techniques to improve outcomes, pinpoint areas for more study or clinical trials, recognize patterns or trends that might inform future research, improve treatment plans based on real-world data, use case studies to illustrate possible treatment journeys, address outcome variability and factors affecting success, and encourage patients to actively participate in their care decisions (63-65). Table 2 describes the quantitative therapeutic outcomes from CRISPR-Based Clinical Trials in Human Medicine

Table 2: Quantitative Therapeutic Outcomes from CRISPR-Based Clinical Trials in Human Medicine (66-75)

Disease/Condition	Therapeutic Approach	Target Gene/Pathway	Trial Phase	Patient Response Rate	Key Quantitative Outcome	Remarks	Reference
Sickle Cell Disease	CRISPR-Cas9 (exa-cel)	BCL11A	Phase I/II	~95%	93% of patients' transfusion-independent at 12 months	Durable clinical remission	66
Beta Thalassemia	CRISPR-Cas9 (exa-cel)	BCL11A	Phase I/II	~90%	89% transfusion-free after one year	FDA-approved (2023)	67
Leber Congenital Amaurosis	In vivo CRISPR (EDIT-101)	CEP290	Phase I/II	~30–50% (variable)	Improved light perception in several patients	First in vivo CRISPR trial	68
Non-Small Cell Lung Cancer	PD-1 knockout T cells	PDCD1	Early Phase I	~28%	Partial response or stable disease	CRISPR-edited T cells used	69
Transthyretin Amyloidosis	CRISPR-Cas9 (NTLA-2001)	TTR	Phase I	100% (dose-dependent)	87% serum TTR reduction with a single dose	In vivo liver editing via LNP	70

Hemophilia B	Gene editing with AAV delivery	F9 gene	Phase I/II	75%	Sustained FIX levels > 30% of normal	Stable clotting factor levels	71
Duchenne Muscular Dystrophy	Exon skipping via CRISPR	DMD	Preclinical	—	Partial restoration of dystrophin expression	Demonstrated in mice and primates	72
Cystic Fibrosis	Base editing (BE)	CFTR	Preclinical	—	Restoration of CFTR function in organoids	Patient-derived cells used	73
Retinitis Pigmentosa	AAV-CRISPR delivery	RHO gene	Preclinical	—	Rescue of photoreceptor structure and function	Animal model validation	74
ALS (C9orf72-related)	CRISPR repeat excision	C9orf72	Preclinical	—	Reduction in toxic RNA foci and dipeptide repeat proteins	Targeted approach for familial ALS	75

ETHICAL AND REGULATORY DILEMMAS

Germline vs Somatic Editing

Germline editing is altering of genes in embryos or reproductive cells that could impact next generations. Because of its extensive effects and unknown long-term repercussions, this raises major ethical questions. Unintended consequences on next generations, such as the possibility of introducing unexpected genetic mutations, altering intricate gene interactions with unpredictable results, and generating new genetic vulnerabilities or health problems (76) are among the main concerns. Furthermore, possible is the development of genetic inequalities, since access to germline modifying technologies may be restricted to wealthy people or nations, hence aggravating current social and economic inequalities. Obtaining informed consent for prospective persons presents yet another ethical conundrum as it is impossible to get consent from future generations impacted by genetic alterations (46). This begs questions about making permanent decisions on behalf of unborn people and the challenges in forecasting long-run effects and weighing possible dangers and advantages. Regulatory and governance difficulties also exist, comprising the requirement of international collaboration and regulation standardisation, balancing scientific advancement with moral considerations, and guaranteeing responsible use while avoiding germline editing technologies abuse (77). Targeting non-reproductive cells and impacting only the treated person, somatic editing offers fewer ethical issues than germline editing does. Nevertheless, it presents major difficulties still. Making sure that therapies are safe and effective calls for thorough testing, long-term monitoring, management of possible off-target effects, and the creation of risk evaluation guidelines. Evaluating therapeutic value, examining alternative treatments, and assessing general health

outcomes (78) helps to balance potential benefits with risks. Ethical issues regarding non-medical applications and social consequences of enhancement technologies arise from the difference between enhancement and therapy. Fair distribution of treatments, solving inequalities, and consideration of economic effects on healthcare systems address issues of equitable access and resource allocation. Informed consent and patient autonomy call for thorough information provision, assuring patient comprehension, and honouring individual choices while considering wider society impacts. Long-term monitoring and follow-up are essential, involving protocols for tracking effects over time, handling unexpected consequences, and developing plans for managing adverse effects (79).

5.2 Informed Consent and Patient Autonomy

In gene editing, informed consent provides difficulties due to several causes. First, the complexity of genetic information and therapies presents challenges including the complicated nature of genetic mechanisms and their interactions, the wide array of gene editing methods with particular applications, and the possibility for off-target effects and unplanned consequences. Second, explaining probabilistic dangers and scientific uncertainties is difficult given the scant data on long-term consequences of gene editing methods, the possible for multigenerational effects and consequences on future progeny, and the challenges in communicating long-term and ambiguous risks. Finally, given the possibility for gene editing to impact not only people but also next generations, ethical issues on human enhancement and genetic alteration, and societal worries about equity, justice, and possible discrimination, balancing individual freedom with social effects is imperative (80,81).

Enhancement of informed consent in gene editing operations might be achieved by several methods. Designing comprehensive education programs for patients is imperative; this entails generating easily available multimedia educational resources, staging interactive seminars and conferences on gene editing ideas, and offering continuous support and resources throughout the decision-making process . Another crucial approach is engaging genetic counsellors in the consent process since they can help patients understand complicated genetic information, have in-depth discussions on genetic ramifications and possible results, and address emotional and psychological aspects of gene editing decisions. Including multi-stage consent processes helps as well as it entails presenting a cooling-off period for meditation and more questions, several consultations to guarantee complete understanding, and repeated re-consent for long-term or multi-phase projects (82).

Several major components fall under gene editing's patient autonomy issues. Respecting individual choices while considering wider society effects includes balancing personal independence with possible repercussions for upcoming generations, resolving issues regarding generating "designer babies" or genetic enhancements, and bearing the influence on genetic variety and evolution. Guaranteeing equal access to gene editing technologies requires tackling socioeconomic inequities in access to gene

editing treatments, creating rules to prevent genetic discrimination in healthcare and jobs, and taking worldwide consequences and possible differences between developed and developing nations into consideration (83). Addressing possible conflicts between patient expectations and medical suggestions requires building procedures for conflict resolution between patients and medical providers, forming ethics committees to review complicated cases, and integrating patient preferences with professional knowledge in shared decision-making models. Other factors include ethical issues in research, openness and public involvement, data protection and privacy, and long-term follow-up and monitoring in addition to regulatory systems and oversight. These elements include developing thorough guidelines, building global collaboration, putting strong protections in place, encouraging frank communication, and setting mechanisms for continuous patient and family contact to solve the difficult moral and practical problems connected with gene editing methods (84,85).

5.3 International Guidelines and Regulatory Gaps

The worldwide character of gene editing research calls for international collaboration with existing guidelines including the Council of Europe's Convention on Human Rights and Biomedicine, the World Health Organization's governance framework for human genome editing, and the International Society for Stem Cell Research guidelines. The UNESCO Universal Declaration on the Human Genome and Human Rights offers additional guidance. Still, there are regulatory issues including mismatched laws across nations, absence of enforceable global standards, possibility for "regulatory havens," quick technical developments outpacing regulatory systems, different degrees of public understanding and acceptance, and difficulty in tracking cross-border research projects (86,87). To close these legal voids, initiatives should concentrate on establishing harmonized international standards, building systems for worldwide inspection and enforcement, encouraging openness and knowledge sharing, creating a global registry for research and clinical trials, implementing standardized reporting criteria, developing international accreditation systems, and establishing a global ethics review board. Ethical considerations in guideline development include balancing scientific progress with safeguards, addressing cultural and religious differences, ensuring diverse stakeholder representation, considering long-term implications of germline editing, addressing concerns about genetic enhancement, ensuring equitable access to technologies and treatments, protecting research participants and future generations, and addressing potential ecological impacts (88). Capacity building and educational programs are essential, including training sessions, public involvement, support for developing nations, and encouragement of interdisciplinary cooperation. Monitoring and enforcement systems should include an international monitoring body, reporting protocols for violations, penalties for non-compliance, and whistleblower protection. Fostering responsible innovation calls for encouraging safer techniques, promoting alternative approaches, and supporting long-term effects research. Addressing

socioeconomic implications includes consideration of effects on healthcare systems, genetic discrimination concerns, and global health disparities (89,90). Genome editing applications span diagnostics, cell conversion, epigenetic modifications, and infection control as shown in fig 3.



Fig 3: Multifaceted Applications of CRISPR Technology in Biomedical Research and Therapeutics

EQUITY AND ACCESSIBILITY IN CRISPR THERAPIES

Cost Barriers and Global Disparities

Although their high costs make widespread accessibility a major obstacle, CRISPR-based treatments have enormous promise for treating genetic abnormalities. The costs related with research, development, and manufacturing of these treatments help to explain their high pricing levels. As a result, high-income nations and low- and middle-income ones have a significant gap in access to CRISPR treatments (91). Several important variables affect worldwide inequality in access to gene therapy. Limited healthcare infrastructure in emerging countries—including poor medical facilities, insufficient cold chain storage for gene therapy goods, and restricted access to sophisticated diagnostic tools for genetic testing—presents major hurdles. Another significant barrier is insufficient funding

for genetic research and clinical trials, which is reflected in a lack of government support for biotechnology research, low private sector funding for gene therapy development, and problems in carrying out big-scale clinical trials in resource-constrained environments (92). The lack of genetic counsellors and specialists, few educational programs concentrating on gene therapy methods, and the brain drain of qualified professionals to high-income countries make clear the paucity of trained personnel to manage and monitor CRISPR treatments. Intellectual property rights and licensing costs pose another obstacle including high costs associated with patent licensing, complicated legal systems surrounding gene editing technologies, and restricted technology transfer agreements between rich and developing nations. Other supporting causes include governmental obstacles in licensing gene therapies in several nations, moral issues and public opinion of gene editing methods, and insufficient knowledge of genetic illnesses in some groups (93).

Possible solutions to overcome cost hurdles include international partnerships to share research costs and knowledge, tiered pricing models based on a country's economic condition, encouragement of generic forms of CRISPR treatments following patent expiration, and investigation of other delivery systems to lower manufacturing expenses. International cooperation might entail building global research alliances for CRISPR technology, developing open-source platforms for information sharing gene editing protocols, and enabling scientist exchanges between high- and low-income nations (94). Tiered pricing models might include differential pricing plans for gene therapies in different countries, negotiating bulk buy agreements for developing nations, and investigating creative funding sources such as impact bonds for healthcare. Encouraging generic CRISPR therapies can be accomplished by backing biosimilar gene therapy development, simplifying regulatory paths for generic CRISPR-based treatments, and encouraging technology transfer to facilitate local production in developing countries (95). Alternative delivery systems to lower manufacturing expenses could include exploring non-viral vector systems for gene distribution, designing off-the-shelf CRISPR therapies for common genetic disorders, and perfecting manufacturing processes to boost efficiency and cut costs. Other solutions involve investing in local capacity building for gene therapy research and development, establishing public-private partnerships to accelerate CRISPR therapy accessibility, developing point-of-care genetic testing tools for resource-limited environments, implementing telemedicine platforms for remote genetic counselling and monitoring, and creating educational programs to increase awareness and acceptance of gene therapies (96).

6.2 Implementation in Low-Resource Settings

Implementing CRISPR therapies in low-resource environments offers difficulties calling for creative solutions. Simplifying delivery methods entails looking into nanoparticle encapsulation for enhanced stability, lyophilization methods for powder-based CRISPR formulas, and creation of steady, room-temperature formulations to get over cold chain

constraints. Oral or topical methods of administration are under investigation to lessen the requirement of specialized equipment, including studies on mucoadhesive preparations and transdermal patches. Local healthcare providers must be trained; attempts should be centered on building relationships with universities for information transfer, creating exchange programs, writing specialized curricula, and setting up remote learning systems with virtual reality simulations and mentoring opportunities (97). Adapting diagnostic tools is crucial; this calls for point-of-care genetic testing equipment, paper-based diagnostics, and isothermal amplification techniques. Patient follow-up and monitoring is increasingly done with mobile health technologies including telehealth systems and smartphone applications. Addressing cultural and ethical issues calls for local communities, ethnographic studies, cooperation with religious and community leaders, regional ethical guideline development, local ethics committee formation, and culturally appropriate informed consent procedures. Using existing healthcare infrastructure entails integrating CRISPR therapies into current public health initiatives, incorporating genetic screening into immunizations, adapting maternal and child health programs, and working with non-governmental groups to reach underprivileged groups via mobile clinics and community health worker networks (98,99).

Public-private collaborations can be investigated as viable funding sources for CRISPR treatment initiatives, including the design of graded pricing schemes based on country income levels and the development of risk-sharing models between governments and pharmaceutical corporations. Creating health impact bonds linked to particular genetic disease outcomes and researching crowdfunding sites for individual patient therapies can help to apply creative financing models such impact bonds or microfinance efforts (100). Dealing with regulatory issues calls for simplified approval processes for CRISPR treatments in low-resource environments, the establishment of fast-track review channels for emergency genetic treatments, and the launching of regional regulatory harmonization programs. Developing mobile applications for adverse event reporting and building central databases for long-term CRISPR treatment results monitoring, post-market surveillance systems fit for local situations can be introduced. Creating regional centres of excellence for CRISPR research, funding local laboratory infrastructure and equipment, and awarding grants and fellowships for bright local scientists are all ways that improving local research and development capability calls for (101). Joint research projects, publications, and international symposia focused on CRISPR applications in resource-limited environments can help to promote collaboration between low- and high-resource locations. Resolving supply chain and logistics issues entails developing local manufacturing capabilities for CRISPR components, exploring modular, portable manufacturing units, and investing in training programs for the local biotechnology workforce (102). Using drone technology for last-mile distribution in distant regions and deploying blockchain-based systems for supply chain transparency and quality control can help to optimize distribution networks for

genetic treatments. Ensuring long-term sustainability and scalability calls for the development of methods for technology transfer and local capacity building, the creation of open-source platforms for sharing CRISPR protocols and tools, and the establishment of regional training hubs for continuous learning and skill acquisition. Implementing monitoring and evaluation frameworks to evaluate influence and direct enhancements entails the development of standard metrics for assessing CRISPR therapy program success and the conduct of frequent stakeholder meetings to find opportunities for modification and expansion (103). Table 3 explores global access and social equity in CRISPR Based treatments.

Table 3: Global Access and Social Equity in CRISPR-Based Treatments (104-109)

Domain	Key Issues	Affected Populations	Current Status	Proposed Solutions	Reference
Cost and Affordability	High therapy costs (>$1 million per treatment)	Low- and middle-income patients	Extremely limited access	Tiered pricing, subsidies, public-private partnerships	104
Global Access	Unequal distribution of clinical trials and tech	Developing countries	Most trials in North America/Europe	Technology transfer, global clinical trial networks	105
Insurance Coverage	Limited or no reimbursement for gene therapies	Uninsured or underinsured patients	Inconsistent across healthcare systems	Policy reform, inclusion in national health coverage	106
Ethical Inclusion	Underrepresentation in trials, biased access	Ethnic minorities, women, children	Lack of diversity in clinical trial cohorts	Inclusive trial design, targeted community engagement	107
Educational Barriers	Low public awareness and scientific literacy	General public, rural populations	Misconceptions about gene editing	Public education campaigns, community workshops	108
Regulatory Delays	Differing regulations and approval processes	Patients in strict jurisdictions	Slower access in some countries	Harmonization of global regulatory frameworks	109

FUTURE PERSPECTIVES AND TECHNOLOGICAL ADVANCEMENTS

Through several developments and applications, CRISPR-based gene editing in human medicine is ready to revolutionise healthcare. Improved delivery methods for CRISPR components, creation of more specific guide RNAs, elimination of off-target effects, and use of new Cas enzymes with

higher specificity will all improve precision and efficiency. Treatment for genetic diseases, immunotherapy for cancer, management for infectious diseases, and regenerative medicine are among the extended therapeutic applications. Personalized medicine developments will allow customized drug development, tailored genetic interventions, and pharmacogenomics (12). In vivo gene editing will enable direct editing of genes inside living organisms, therefore treating diseases in adult patients through tissue-specific delivery systems. Multiplex gene editing will let simultaneous modification of several genes, therefore tackle complicated genetic diseases and improve cellular activities. Clinical potentials include curative treatments for previously incurable genetic diseases, enhanced cancer therapies, prevention of hereditary disorders, and improved organ transplantation outcomes. Technological innovations will integrate artificial intelligence, develop novel CRISPR-associated enzymes, and advance gene therapy vector design (6,7). Diagnostic applications will utilize CRISPR-based tools for rapid disease detection and point-of-care genetic testing. Combination therapies will integrate CRISPR with other therapeutic modalities for synergistic effects. Ethical considerations and regulatory frameworks will address concerns about germline editing, ensure equitable access, regulate non-therapeutic enhancements, protect genetic information privacy, balance progress with safety, establish guidelines, and promote public engagement. Long-term monitoring and follow-up will track effects and assess safety and efficacy. Collaborative research initiatives will foster international cooperation and interdisciplinary approaches. Maintaining a balance between scientific advancement and moral considerations is crucial as CRISPR technology develops to guarantee responsible growth and use for human health benefits (97,110).

8. CONCLUSION

CRISPR-based gene editing has transformed human medicine by giving previously unimaginable potential for the treatment of genetic diseases, cancer, and infectious infections. The clinical uses, therapeutic effects, and ethical concerns related to CRISPR technology are examined in this study. Successful therapy of monogenic illnesses including β-thalassemia and sickle cell disease is among clinical applications and therapeutic results; possible uses exist in other single-gene diseases. For oncology, CRISPR improves immunotherapy results, targets oncogenes and tumour suppressor genes, and enhances CAR-T cell treatment. For infectious illnesses, antiviral treatments for HIV, hepatitis B, and herpes simplex virus are under development, with possible applications in emerging viral threats. CRISPR helps to edit immune cells and repair genetic predispositions in autoimmune diseases. Difficulties and ethical questions include germline editing, which raises questions regarding inherited genetic changes and long-term effects on human development. Other major problems include informed consent, legal loopholes, off-target effects, accessibility and equity issues. CRISPR technology's future will be improving accessibility, creating ethical guidelines, expanding therapeutic uses, creating affordable delivery systems, and conducting long-term safety investigations. Understanding

CRISPR's whole promise in human medicine calls for a balanced approach that maximizes therapeutic advantages while navigating moral issues and guaranteeing fair access. Ongoing ethical debates, international cooperation, and research are critical for using this potent tool judiciously and successfully.

References

1. Li ZH, Wang J, Xu JP, Wang J, Yang X. Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research. Military Med Res. 2023 Mar 10;10(1):12.

2. Mushtaq M, Ahmad Dar A, Skalicky M, Tyagi A, Bhagat N, Basu U, et al. CRISPR-Based Genome Editing Tools: Insights into Technological Breakthroughs and Future Challenges. Genes. 2021 May 24;12(6):797.

3. Hwarari D, Radani Y, Ke Y, Chen J, Yang L. CRISPR/Cas genome editing in plants: mechanisms, applications, and overcoming bottlenecks. Funct Integr Genomics. 2024 Apr;24(2):50.

4. Perisse IV, Fan Z, Singina GN, White KL, Polejaeva IA. Improvements in Gene Editing Technology Boost Its Applications in Livestock. Front Genet. 2021 Jan 8;11:614688.

5. Alagumuthu M, Kunju JJ, Suresh J. CRISPR in medical microbiology–the try and trial towards future. Next Research. 2025 Mar :100276.

6. Ding S, Liu J, Han X, Tang M. CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy. IJMS. 2023 Nov 15;24(22):16325.

7. Zhang ML, Li HB, Jin Y. Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy. Front Genet. 2024 Apr 11;15:1364742.

8. Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precision Clinical Medicine. 2021 Sep 16;4(3):179–91.

9. Wang SW, Gao C, Zheng YM, Yi L, Lu JC, Huang XY, et al. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer. 2022 Feb 21;21(1):57.

10. Shojaei Baghini S, Gardanova ZR, Abadi SAH, Zaman BA, İlhan A, Shomali N, et al. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool. Cell Mol Biol Lett. 2022 Dec;27(1):35.

11. Asmamaw Mengstie M, Teshome Azezew M, Asmamaw Dejenie T, Teshome AA, Tadele Admasu F, Behaile Teklemariam A, et al. Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing. BTT. 2024 Jan;Volume 18:21–8.

12. Teng M, Yao Y, Nair V, Luo J. Latest Advances of Virology Research Using CRISPR/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development. Viruses. 2021 Apr 28;13(5):779.

13. Movahedi A, Aghaei-Dargiri S, Li H, Zhuge Q, Sun W. CRISPR Variants for Gene Editing in Plants: Biosafety Risks and Future Directions. IJMS. 2023 Nov 13;24(22):16241.

14. Chen Y, Ping Y. Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing. Acc Chem Res. 2023 Aug 15;56(16):2185–96.

15. Huang X, Yang D, Zhang J, Xu J, Chen YE. Recent Advances in Improving Gene-Editing Specificity through CRISPR–Cas9 Nuclease Engineering. Cells. 2022 Jul 13;11(14):2186.

16. Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR/Cas9 gene editing. Front Bioeng Biotechnol. 2023 Mar 9;11:1143157.

17. Zou RS, Liu Y, Gaido OER, Konig MF, Mog BJ, Shen LL, et al. Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+. Nat Methods. 2023 May;20(5):706–13.

18. Charlier J, Nadon R, Makarenkov V. Accurate deep learning off-target prediction with novel sgRNA-DNA sequence encoding in CRISPR-Cas9 gene editing. Kelso J, editor. Bioinformatics. 2021 Aug 25;37(16):2299–307.

19. Naeem M, Majeed S, Hoque MZ, Ahmad I. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing. Cells. 2020 Jul 2;9(7):1608.

20. Naz Z, Fareed M, Chaudhary AR, Snigdha NT, Zafar A, Alsaidan OA, Mangu K, Ahmad S, Aslam M, Rizwanullah M. Exploring the therapeutic potential of ligand-decorated nanostructured lipid carriers for targeted solid tumor therapy. International Journal of Pharmaceutics. 2025 May:125687.

21. Bairqdar A, Karitskaya PE, Stepanov GA. Expanding Horizons of CRISPR/Cas Technology: Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy. International Journal of Molecular Sciences. 2024 Dec ;25(24):13321.

22. Haque US, Yokota T. Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging Therapies. Degenerative Neurological and Neuromuscular Disease. 2025 Dec 31:17-40. https://doi.org/10.2147/DNND.S495536

23. Aleman TS, Uyhazi KE, Roman AJ, Weber ML, O'Neil EC, Swider M, Sumaroka A, Maguire KH, Aleman EM, Santos AJ, Kim RJ. Recovery of Cone-Mediated Vision in Lebercilin-Associated Severe Retinal Ciliopathy (LCA5) after Gene Therapy: One Year Results of a Phase Ib/IIa Trial. Molecular Therapy. 2025

24. Shams F, Sharif E, Abbasi-Kenarsari H, Hashemi N, Hosseini MS, Heidari N, Noori E, Amini AH, Bazrgar M, Rouhani M, Teng Y. CRISPR/Cas9 technology for modifying immune checkpoint in CAR-T cell therapy for hematopoietic malignancies. Current Gene Therapy. 2025 Apr .

25. Wang JW, Liu JH, Xun JJ. CCR5 gene editing and HIV immunotherapy: current understandings, challenges, and future directions. Frontiers in Immunology. 2025 Jun ;16:1590690.

26. Teffera ZH, Abebaw D, Akelew Y, Belayneh M, Mesganaw Shitie B, Selabat B, Tefera S, Belew H, Gedefaw L. Novel therapeutic vaccine development strategies targeting high risk HPV16/18-E6/7 oncoproteins, their immunogenicity, and efficacy associated with cervical intraepithelial neoplasia and cervical cancer: a systematic review. Discover Viruses. 2025 May ;2(1):14.

27. Piao X, Li D, Liu H, Guo Q, Yu Y. Advances in gene and cellular therapeutic approaches for Huntington's disease. Protein & Cell. 2025 May;16(5):307-37.

28. Mizielinska S, Hautbergue GM, Gendron TF, van Blitterswijk M, Hardiman O, Ravits J, Isaacs AM, Rademakers R. Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics. The Lancet Neurology. 2025 Mar ;24(3):261-74.

29. Da Dalt L, Baragetti A, Norata GD. Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies. Expert Opinion on Therapeutic Targets. 2025 Mar ;29(3):137-57.

30. Almotiri A, Abogosh A, Abdelfattah A, Alowaisy D, Rodrigues NP. Treating genetic blood disorders in the era of CRISPR-mediated genome editing. Molecular Therapy. 2025 Jun ;33(6):2645-62.

31. Thomas H, Carlisle RC. Progress in Gene Therapy for Hereditary Tyrosinemia Type 1. Pharmaceutics. 2025 Mar ;17(3):387.

32. Mustfa SA, Dimitrievska M, Wang C, Gu C, Sun N, Romańczuk K, Karpinski P, Łaczmański Ł, McGrath JA, Jacków-Malinowska J, Chiappini C. Porous Silicon Nanoneedles Efficiently Deliver Adenine Base Editor to Correct a Recurrent Pathogenic COL7A1 Variant in Recessive Dystrophic Epidermolysis Bullosa. Advanced Materials. 2025 Apr;37(17):2414728.

33. Lidonnici MR, Scaramuzza S, Ferrari G. Gene Therapy for Hemoglobinopathies.

Human Gene Therapy. 2023 Sep 1;34(17–18):793–807.

34. Hu J, Zhong Y, Xu P, Xin L, Zhu X, Jiang X, et al. β-Thalassemia gene editing therapy: Advancements and difficulties. Medicine. 2024 May 3;103(18):e38036.

35. Zeng S, Lei S, Qu C, Wang Y, Teng S, Huang P. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia. Hum Genet. 2023 Dec;142(12):1677–703.

36. Sivalingam AM, Sureshkumar DD. Cerebellar pathology in forensic and clinical neuroscience. Ageing Research Reviews. 2025 Feb 21:102697.

37. Finotti A, Gambari R. Combined approaches for increasing fetal hemoglobin (HbF) and de novo production of adult hemoglobin (HbA) in erythroid cells from β-thalassemia patients: treatment with HbF inducers and CRISPR-Cas9 based genome editing. Front Genome Ed. 2023 Jul 17;5:1204536.

38. Allemailem KS, Alsahli MA, Almatroudi A, Alrumaihi F, Al Abdulmonem W, Moawad AA, et al. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management. IJN. 2023 Sep;Volume 18:5531–59.

39. Afolabi LO, Afolabi MO, Sani MM, Okunowo WO, Yan D, Chen L, et al. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. Clin & Trans Imm. 2021 Jan;10(6):e1286.

40. Zhang Z, Wang H, Yan Q, Cui J, Chen Y, Ruan S, et al. Genome-wide CRISPR/Cas9 screening for drug resistance in tumors. Front Pharmacol. 2023 Nov 21;14:1284610.

41. Wei J, Li W, Zhang P, Guo F, Liu M. Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. Mol Cancer. 2024 Dec 26;23(1):279.

42. To KKW, Cho WC. Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy. Pharmaceutics. 2023 Aug 21;15(8):2166.

43. Gu XY, Huo JL, Yu ZY, Jiang JC, Xu YX, Zhao LJ. Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects. Oncologie. 2024 Jan 23;26(1):9–25.

44. Gupta PK, Saxena A. HIV/AIDS: Current Updates on the Disease, Treatment and Prevention. Proc Natl Acad Sci, India, Sect B Biol Sci. 2021 Sep;91(3):495–510.

45. Liu Y, Binda CS, Berkhout B, Das AT. CRISPR-Cas attack of HIV-1 proviral DNA can cause unintended deletion of surrounding cellular DNA. Kirchhoff F, editor. J Virol. 2023 Dec 21;97(12):e01334-23.

46. Kolanu ND. CRISPR–Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications. Glob Med Genet. 2024 Jan;11(01):113–22.

47. Li P, Wang L, Yang J, Di LJ, Li J. Applications of the CRISPR-Cas system for infectious disease diagnostics. Expert Review of Molecular Diagnostics. 2021 Jul 3;21(7):723–32.

48. Zahedipour F, Zahedipour F, Zamani P, Jaafari MR, Sahebkar A. Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications. Virus Research. 2024 Mar;341:199314.

49. Zhang Y, Zhang X, Wang P, Wu Y, Chow SC. A Proposed Confidence Ellipse Approach for Benefit-Risk Assessment in Clinical Trials. Ther Innov Regul Sci. 2025 May;59(3):606–18.

50. Ciolino JD, Kaizer AM, Bonner LB. Guidance on interim analysis methods in clinical trials. J Clin Trans Sci. 2023;7(1):e124.

51. Gikandi A, Hallet J, Koerkamp BG, Clark CJ, Lillemoe KD, Narayan RR, et al. Distinguishing Clinical From Statistical Significances in Contemporary Comparative Effectiveness Research. Annals of Surgery. 2024 Jun;279(6):907–12.

52. Wang SV, Schneeweiss S, RCT-DUPLICATE Initiative, Franklin JM, Desai RJ, Feldman W, et al. Emulation of Randomized Clinical

Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials. JAMA. 2023 Apr 25;329(16):1376.

53. Singh P, Burden AM, Natanegara F, Beckman RA. Design and Execution of Sustainable Decentralized Clinical Trials. Clin Pharma and Therapeutics. 2023 Oct;114(4):802–9.

54. Michaeli DT, Michaeli T, Albers S, Michaeli JC. Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications. BMJ EBM. 2024 Oct;29(5):333–41.

55. Sinha SD, Chary Sriramadasu S, Raphael R, Roy S. Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges. Pharm Med. 2024 Mar;38(2):109–20.

56. Feinberg BA, Zettler ME, Klink AJ, Lee CH, Gajra A, Kish JK. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials. JAMA Netw Open. 2021 Feb 25;4(2):e2036741.

57. Nambiema A, Sembajwe G, Lam J, Woodruff T, Mandrioli D, Chartres N, et al. A Protocol for the Use of Case Reports/Studies and Case Series in Systematic Reviews for Clinical Toxicology. Front Med. 2021 Sep 6;8:708380.

58. Domingo-Fernández D, Gadiya Y, Preto AJ, Krettler CA, Mubeen S, Allen A, et al. Natural Products Have Increased Rates of Clinical Trial Success throughout the Drug Development Process. J Nat Prod. 2024 Jul 26;87(7):1844–51.

59. Sydney Anuyah, Mallika K Singh, Hope Nyavor. Advancing clinical trial outcomes using deep learning and predictive modelling: bridging precision medicine and patient-centered care. World J Adv Res Rev. 2024 Dec 30;24(3):001–25.

60. Azzolina D, Berchialla P, Gregori D, Baldi I. Prior Elicitation for Use in Clinical Trial Design and Analysis: A Literature Review. IJERPH. 2021 Feb 13;18(4):1833.

61. Chandanabhumma PP, Swaminathan S, Cabrera LM, Hou H, Yang G, Kim KD, et al. Enhancing Qualitative and Quantitative Data Linkages in Complex Mixed Methods Designs: Illustrations From a Multi-phase Healthcare Delivery Study. Journal of Mixed Methods Research. 2024 Jul;18(3):235–46.

62. Smajic E, Avdic D, Pasic A, Prcic A, Stancic M. Mixed Methodology of Scientific Research in Healthcare. Acta Inform Med. 2022;30(1):57.

63. Schlunegger MC, Zumstein-Shaha M, Palm R. Methodologic and Data-Analysis Triangulation in Case Studies: A Scoping Review. West J Nurs Res. 2024 Aug;46(8):611–22.

64. Richards DA, Bazeley P, Borglin G, Craig P, Emsley R, Frost J, et al. Integrating quantitative and qualitative data and findings when undertaking randomised controlled trials. BMJ Open. 2019 Nov;9(11):e032081.

65. Im D, Pyo J, Lee H, Jung H, Ock M. Qualitative Research in Healthcare: Data Analysis. J Prev Med Public Health. 2023 Mar 31;56(2):100–10.

66. Cetin B, Erendor F, Eksi YE, Sanlioglu AD, Sanlioglu S. Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. Expert Reviews in Molecular Medicine. 2025 Mar :1-96.

67. George CA, Sahu SU, de Oñate L, Souza BS, Wilson RC. Genome editing therapy for the blood: ex vivo success and in vivo prospects. The CRISPR Journal. 2024 Oct ;7(5):231-48.

68. Gong X, Hertle RW. Infantile Nystagmus Syndrome—Associated Inherited Retinal Diseases: Perspectives from Gene Therapy Clinical Trials. Life. 2024 Oct ;14(11):1356.

69. Ziółkowska-Suchanek I, Rozwadowska N. Advancements in Gene Therapy for Non-Small Cell Lung Cancer: Current Approaches and Future Prospects. Genes. 2025 May ;16(5):569.

70. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O'Connell D, Walsh KR, Wood K, Phillips J. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England

Journal of Medicine. 2021 Aug ;385(6):493-502.

71. Soroka AB, Feoktistova SG, Mityaeva ON, Volchkov PY. Gene therapy approaches for the treatment of hemophilia B. International Journal of Molecular Sciences. 2023 Jun ;24(13):10766.

72. Padmaswari MH, Agrawal S, Nelson CE. Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping. Journal of Neuromuscular Diseases. 2025 May;12(3):424-34.

73. Geurts MH, de Poel E, Pleguezuelos-Manzano C, Oka R, Carrillo L, Andersson-Rolf A, Boretto M, Brunsveld JE, van Boxtel R, Beekman JM, Clevers H. Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids. Life science alliance. 2021 Oct ;4(10).

74. Wu WH, Tsai YT, Huang IW, Cheng CH, Hsu CW, Cui X, Ryu J, Quinn PM, Caruso SM, Lin CS, Tsang SH. CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa. Molecular Therapy. 2022 Apr ;30(4):1407-20.

75. Cattaneo M, Giagnorio E, Lauria G, Marcuzzo S. Therapeutic Approaches for C9ORF72-Related ALS: Current Strategies and Future Horizons. International Journal of Molecular Sciences. 2025 Jun ;26(13):6268.

76. Ayanoğlu FB, ElçiN AE, ElçiN YM. Bioethical issues in genome editing by CRISPR-Cas9 technology. Turk J Biol. 2020 Apr ;44(2):110–20.

77. Singh K, Bhushan B, Kumar S, Singh S, Macadangdang RR, Pandey E, et al. Precision Genome Editing Techniques in Gene Therapy: Current Stateand Future Prospects. CGT. 2024 Oct;24(5):377–94.

78. Suh S, Choi EH, Raguram A, Liu DR, Palczewski K. Precision genome editing in the eye. Proc Natl Acad Sci USA. 2022 Sep;119(39):e2210104119.

79. Arroyo-Olarte RD, Bravo Rodríguez R, Morales-Ríos E. Genome Editing in Bacteria: CRISPR-Cas and Beyond. Microorganisms. 2021 Apr;9(4):844.

80. Kazemian P, Yu SY, Thomson SB, Birkenshaw A, Leavitt BR, Ross CJD. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components. Mol Pharmaceutics. 2022 Jun ;19(6):1669–86.

81. Deneault E. Recent Therapeutic Gene Editing Applications to Genetic Disorders. CIMB. 2024 Apr ;46(5):4147–85.

82. Chen S, Chen D, Liu B, Haisma HJ. Modulating CRISPR/Cas9 genome-editing activity by small molecules. Drug Discovery Today. 2022 Apr;27(4):951–66.

83. Baines R, Stevens S, Austin D, Anil K, Bradwell H, Cooper L, et al. Patient and Public Willingness to Share Personal Health Data for Third-Party or Secondary Uses: Systematic Review. J Med Internet Res. 2024 Mar 5;26:e50421.

84. Jane Osareme Ogugua, Evangel Chinyere Anyanwu, Tolulope Olorunsogo, Chinedu Paschal Maduka, Oluwatoyin Ayo-Farai. Ethics and strategy in vaccination: A review of public health policies and practices. Int J Sci Res Arch. 2024 Jan 30;11(1):883–95.

85. Torras C. Ethics of Social Robotics: Individual and Societal Concerns and Opportunities. Annual Review of Control, Robotics, and Autonomous Systems. 2024 Jul 10;7(1):1–18.

86. Martín-Valmaseda M, Devin SR, Ortuño-Hernández G, Pérez-Caselles C, Mahdavi SME, Bujdoso G, et al. CRISPR/Cas as a Genome-Editing Technique in Fruit Tree Breeding. IJMS. 2023 Nov 23;24(23):16656.

87. Zhou S, Li Y, Wu Q, Gong C. Nanotechnology-based CRISPR/Cas9 delivery system for genome editing in cancer treatment. MedComm – Biomaterials and Applications. 2024 Mar;3(1):e70.

88. Tsakirpaloglou N, Septiningsih EM, Thomson MJ. Guidelines for Performing CRISPR/Cas9 Genome Editing for Gene Validation and Trait Improvement in Crops. Plants. 2023 Oct 13;12(20):3564.

89. Qu Y, Huang K, Cousins H, Johnson WA, Yin D, Shah M, et al. CRISPR-GPT: An LLM Agent for Automated Design of Gene-Editing

Experiments [Internet]. Bioinformatics; 2024 [cited 2025 Jun 26]. Available from: http://biorxiv.org/lookup/doi/10.1101/2024.04.25.591003

90. Pacesa M, Pelea O, Jinek M. Past, present, and future of CRISPR genome editing technologies. Cell. 2024 Feb;187(5):1076–100.

91. Subica AM. CRISPR in Public Health: The Health Equity Implications and Role of Community in Gene-Editing Research and Applications. Am J Public Health. 2023 Aug;113(8):874–82.

92. Youssef E, Fletcher B, Palmer D. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. Front Med. 2025 Jan 13;11:1527600.

93. Rueda J, De Miguel Beriain Í, Montoliu L. Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative. The CRISPR Journal. 2024 Oct 1;7(5):220–6.

94. Tang X, Zhang Y. Beyond knockouts: fine-tuning regulation of gene expression in plants with CRISPR-Cas -based promoter editing. New Phytologist. 2023 Aug;239(3):868–74.

95. Morshedzadeh F, Ghanei M, Lotfi M, Ghasemi M, Ahmadi M, Najari-Hanjani P, et al. An Update on the Application of CRISPR Technology in Clinical Practice. Mol Biotechnol. 2024 Feb;66(2):179–97.

96. Demirer GS, Silva TN, Jackson CT, Thomas JB, W. Ehrhardt D, Rhee SY, et al. Nanotechnology to advance CRISPR–Cas genetic engineering of plants. Nat Nanotechnol. 2021 Mar;16(3):243–50.

97. Far BF, Naimi-Jamal MR, Ahmadi S, Rabiee N. Advanced Ca-doped MOF nanocarriers for Co-delivery of Doxorubicin/pCRISPR. Nano Materials Science. 2024

98. Tang N, Ji Q. Miniature CRISPR-Cas12 Systems: Mechanisms, Engineering, and Genome Editing Applications. ACS Chem Biol. 2024 Jul 19;19(7):1399–408.

99. Ghouneimy A, Mahas A, Marsic T, Aman R, Mahfouz M. CRISPR-Based Diagnostics: Challenges and Potential Solutions toward Point-of-Care Applications. ACS Synth Biol. 2023 Jan 20;12(1):1–16.

100. Iqbal Z, Rehman K, Xia J, Shabbir M, Zaman M, Liang Y, et al. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing. Biomater Sci. 2023;11(11):3762–83.

101. Zhang S, Wang Y, Mao D, Wang Y, Zhang H, Pan Y, et al. Current trends of clinical trials involving CRISPR/Cas systems. Front Med. 2023 Nov ;10:1292452.

102. Lei T, Wang Y, Zhang Y, Yang Y, Cao J, Huang J, et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024 Dec;38(12):2517–43.

103. Hryhorowicz M, Lipiński D, Zeyland J. Evolution of CRISPR/Cas Systems for Precise Genome Editing. IJMS. 2023 Sep 18;24(18):14233.

104. Abass LA, Usuemerai PA, Ibikunle OE, Alemede V, Nwankwo EI, Mbata AO. Public-private partnerships to enhance healthcare access and affordability. Int J Multidiscip Res Growth Eval. 2024 Jul;5(4):1327-44.

105. Vieira M, Andia T, Karim O, Srishti SA, Pineda SA, Alonso Ruiz A, Large K, Liu Y, Moon S, Naher N, Siddiqui A. Rising pharmaceutical innovation in the Global South: a landscape study. Journal of Pharmaceutical Policy and Practice. 2023 Nov ;16(1):155.

106. Horrow C, Kesselheim AS. Confronting high costs and clinical uncertainty: innovative payment models for gene therapies: study examines costs, clinical uncertainties, and payment models for gene therapies. Health Affairs. 2023 Nov ;42(11):1532-40.

107. Keegan G, Crown A, Joseph KA. Diversity, equity, and inclusion in clinical trials. Surgical Oncology Clinics. 2023 Jan ;32(1):221-32.

108. Altinay Z. Perceptions of science and boundary crossing in human gene editing acceptance. Ethics, Medicine and Public Health. 2025 Jan ;33:101141.

109. Amaral C, Paiva M, Rodrigues AR, Veiga F, Bell V. Global regulatory challenges for medical devices: impact on innovation and market access. Applied Sciences. 2024 Oct ;14(20):9304.

110. Saber Sichani A, Ranjbar M, Baneshi M, Torabi Zadeh F, Fallahi J. A Review on Advanced CRISPR-Based Genome-Editing Tools: Base Editing and Prime Editing. Mol Biotechnol. 2023 Jun;65(6):849–60.

To cite this article: Saghya Infant Shofia, Sundaram V, Sowndharya Balamurugan B, Mathan Muthu C M, Saravanan A, Jenila Rani D. CRISPR-Based Gene Editing in Human Medicine: Clinical Potentials and Ethical Dilemmas. BMFJ 2025;42(10):71-97.